BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang B, Liang X, Tang F, Zhang J, Zeng S, Jin S, Zhou L, Kudo Y, Qi G. Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma. Int J Oncol 2015;47:2208-16. [PMID: 26497847 DOI: 10.3892/ijo.2015.3214] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Cheng J, Guo J, North BJ, Wang B, Cui C, Li H, Tao K, Zhang L, Wei W. Functional analysis of deubiquitylating enzymes in tumorigenesis and development. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2019;1872:188312. [DOI: 10.1016/j.bbcan.2019.188312] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
2 Ao N, Wang L, Liu Y. Prognostic and clinicopathological significance of ubiquitin-specific protease 22 overexpression in cancers: evidence from a meta-analysis. Onco Targets Ther 2017;10:5533-40. [PMID: 29200868 DOI: 10.2147/OTT.S139458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Zhang J, Luo N, Tian Y, Li J, Yang X, Yin H, Xiao C, Sheng J, Li Y, Tang B, Li R. USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt. Oncotarget 2017;8:24728-40. [PMID: 28445968 DOI: 10.18632/oncotarget.15798] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
4 Si T, Ning X, Zhao H, Zhang M, Huang P, Hu Z, Yang L, Lin L. microRNA-9-5p regulates the mitochondrial function of hepatocellular carcinoma cells through suppressing PDK4. Cancer Gene Ther 2021;28:706-18. [PMID: 33257740 DOI: 10.1038/s41417-020-00253-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Liu T, Liu J, Chen Q, Jin S, Mi S, Shao W, Kudo Y, Zeng S, Qi G. Expression of USP22 and the chromosomal passenger complex is an indicator of malignant progression in oral squamous cell carcinoma. Oncol Lett 2019;17:2040-6. [PMID: 30675271 DOI: 10.3892/ol.2018.9837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 Wang H, Jin S, Lu H, Mi S, Shao W, Zuo X, Yin H, Zeng S, Shimamoto F, Qi G. Expression of survivin, MUC2 and MUC5 in colorectal cancer and their association with clinicopathological characteristics. Oncol Lett 2017;14:1011-6. [PMID: 28693267 DOI: 10.3892/ol.2017.6218] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
7 Wang S, Zhong X, Wang C, Luo H, Lin L, Sun H, Sun G, Zeng K, Zou R, Liu W, Sun N, Song H, Liu W, Zhang Q, Liao Z, Teng X, Zhou T, Sun X, Zhao Y. USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer. Cell Death Differ 2020;27:3131-45. [PMID: 32494025 DOI: 10.1038/s41418-020-0568-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
8 Yu J, Wang Z, Zhang H, Wang Y, Li DQ. Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma. World J Gastroenterol 2021; 27(43): 7546-7562 [PMID: 34887648 DOI: 10.3748/wjg.v27.i43.7546] [Reference Citation Analysis]
9 Yang X, Zang H, Luo Y, Wu J, Fang Z, Zhu W, Li Y. High expression of USP22 predicts poor prognosis and advanced clinicopathological features in solid tumors: a meta-analysis. Onco Targets Ther 2018;11:3035-46. [PMID: 29872315 DOI: 10.2147/OTT.S148662] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
10 Kim MJ, Choi B, Kim JY, Min Y, Kwon DH, Son J, Lee JS, Lee JS, Chun E, Lee KY. USP8 regulates liver cancer progression via the inhibition of TRAF6-mediated signal for NF-κB activation and autophagy induction by TLR4. Transl Oncol 2021;15:101250. [PMID: 34688043 DOI: 10.1016/j.tranon.2021.101250] [Reference Citation Analysis]
11 Wen X, Ling S, Wu W, Shan Q, Liu P, Wang C, Wei X, Ding W, Teng X, Xu X. Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma. Dig Dis Sci 2020;65:1064-73. [PMID: 31587155 DOI: 10.1007/s10620-019-05844-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Li W, Atanassov BS, Lan X, Mohan RD, Swanson SK, Farria AT, Florens L, Washburn MP, Workman JL, Dent SYR. Cytoplasmic ATXN7L3B Interferes with Nuclear Functions of the SAGA Deubiquitinase Module. Mol Cell Biol 2016;36:2855-66. [PMID: 27601583 DOI: 10.1128/MCB.00193-16] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yang X, Jin J, Yang J, Zhou L, Mi S, Qi G. Expression of Ubiquitin-specific protease 7 in oral squamous cell carcinoma promotes tumor cell proliferation and invasion. Genet Mol Biol 2021;44:e20210058. [PMID: 34812471 DOI: 10.1590/1678-4685-GMB-2021-0058] [Reference Citation Analysis]
14 Wei Y, Jiang Z, Lu J. USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization. Oncol Lett 2021;21:394. [PMID: 33777217 DOI: 10.3892/ol.2021.12655] [Reference Citation Analysis]
15 Huang Y, Nie M, Li C, Zhao Y, Li J, Zhou L, Wang L. RLIM suppresses hepatocellular carcinogenesis by up-regulating p15 and p21. Oncotarget 2017;8:83075-87. [PMID: 29137325 DOI: 10.18632/oncotarget.20904] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Xu G, Cai J, Wang L, Jiang L, Huang J, Hu R, Ding F. MicroRNA-30e-5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3 signaling. Exp Cell Res 2018;362:268-78. [PMID: 29174979 DOI: 10.1016/j.yexcr.2017.11.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
17 Pinto-Fernandez A, Kessler BM. DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets. Front Genet 2016;7:133. [PMID: 27516771 DOI: 10.3389/fgene.2016.00133] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
18 Qi G, Kudo Y, Tang B, Liu T, Jin S, Liu J, Zuo X, Mi S, Shao W, Ma X, Tsunematsu T, Ishimaru N, Zeng S, Tatsuka M, Shimamoto F. PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer. Oncotarget 2016;7:18812-24. [PMID: 26934315 DOI: 10.18632/oncotarget.7712] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
19 Lin Y, Zhong H, Sun B, Peng Y, Lu F, Chen M, Zhu M, Huang J. USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin. Oncol Lett 2020;20:246. [PMID: 32973959 DOI: 10.3892/ol.2020.12108] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Yu Y, Shang R, Chen Y, Li J, Liang Z, Hu J, Liu K, Chen C. Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma. Biomedicine & Pharmacotherapy 2018;100:108-15. [DOI: 10.1016/j.biopha.2018.01.132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
21 Liao Y, Liang X, Liang W, Li Z, Wang Y, Wang L, Zhen S, Tang B, Wang Z. High expression of ubiquitin carboxyl-terminal hydrolase 22 is associated with poor prognosis in hepatitis B virus-associated liver cancer. Oncol Lett 2019;17:5159-68. [PMID: 31186731 DOI: 10.3892/ol.2019.10154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Shang H, Hao ZQ, Fu XB, Hua XD, Ma ZH, Ai FL, Feng ZQ, Wang K, Li WX, Li B. Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway. Oncol Lett 2018;15:5966-70. [PMID: 29563999 DOI: 10.3892/ol.2018.8033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Sun N, Zhong X, Wang S, Zeng K, Sun H, Sun G, Zou R, Liu W, Liu W, Lin L, Song H, Lv C, Wang C, Zhao Y. ATXN7L3 positively regulates SMAD7 transcription in hepatocellular carcinoma with growth inhibitory function. EBioMedicine 2020;62:103108. [PMID: 33186807 DOI: 10.1016/j.ebiom.2020.103108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Leberfarb EY, Degtyareva AO, Brusentsov II, Maximov VN, Voevoda MI, Autenshlus AI, Morozov DV, Sokolov AV, Merkulova TI. Potential regulatory SNPs in the ATXN7L3B and KRT15 genes are associated with gender-specific colorectal cancer risk. Per Med 2020;17:43-54. [PMID: 31797724 DOI: 10.2217/pme-2019-0059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]